Huahai Pharmaceutical announced that the company's net profit attributable to shareholders of listed companies for the first quarter of 2024, after deducting non-recurring profit and loss, is expected to be between RMB 292.2 million and RMB 30.5 million. Compared with the same period of the previous year (statutory disclosure data), it will increase by about 103.65 million yuan to 131.95 million yuan, an increase of about 55% to 70% over the previous year.
华海药业：2024年一季度业绩预增55%到70%
Huahai Pharmaceutical: Results for the first quarter of 2024 are expected to increase by 55% to 70%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.